结核病免疫辅助治疗现状与挑战

doi:10.19982/j.issn.1000-6621.20220346

摘要/Abstract

摘要：

关键词: 结核, 免疫, 治疗应用, 评论

中图分类号:

安慧茹, 吴雪琼. 结核病免疫辅助治疗现状与挑战[J]. 中国防痨杂志, 2022, 44(10): 983-986. doi: 10.19982/j.issn.1000-6621.20220346

参考文献 30

[1]	World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021.
[2]	World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
[3]	Sampath P, Moideen K, Ranganathan UD, et al. Monocyte Subsets: Phenotypes and Function in Tuberculosis Infection. Front Immunol, 2018, 9:1726. doi: 10.3389/fimmu.2018.01726. doi: 10.3389/fimmu.2018.01726 pmid: 30105020
[4]	Croft M. Co-stimulatory members of the TNFR family:keys to effective T-cell immunity? Nat Rev Immunol, 2003, 3(8):609-620. doi: 10.1038/nri1148. doi: 10.1038/nri1148 URL
[5]	Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol, 2009, 27:393-422. doi: 10.1146/annurev.immunol.021908.132703. doi: 10.1146/annurev.immunol.021908.132703
[6]	Urdahl KB, Shafiani S, Ernst JD. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol, 2011, 4(3):288-293. doi: 10.1038/mi.2011.10. doi: 10.1038/mi.2011.10 pmid: 21451503
[7]	Morgan J, Muskat K, Tippalagama R, et al. Classical CD4 T cells as the cornerstone of antimycobacterial immunity. Immunol Rev, 2021, 301(1):10-29. doi: 10.1111/imr.12963. doi: 10.1111/imr.12963 pmid: 33751597
[8]	An HR, Bai XJ, Liang JQ, et al. The relationship between absolute counts of lymphocyte subsets and clinical features in patients with pulmonary tuberculosis. Clin Respir J, 2022, 16(5):369-379. doi: 10.1111/crj.13490. doi: 10.1111/crj.13490 URL
[9]	Guglielmetti L, Cazzadori A, Conti M, et al. Lymphocyte subpopulations in active tuberculosis: association with disease severity and the QFT-GIT assay. Int J Tuberc Lung Dis, 2013, 17(6):825-828. doi: 10.5588/ijtld.12.0361. doi: 10.5588/ijtld.12.0361 pmid: 23676170
[10]	Morais-Papini TF, Coelho-Dos-Reis JGA, Wendling APB, et al. Systemic Immunological changes in patients with distinct clinical outcomes during Mycobacterium tuberculosis infection. Immunobiology, 2017, 222(11):1014-1024. doi: 10.1016/j.imbio.2017.05.016. doi: S0171-2985(17)30099-2 pmid: 28619539
[11]	傅小燕, 吴桂辉, 黄涛, 等. 活动性肺结核合并糖尿病患者的T细胞亚群与血糖水平的相关性研究. 中西医结合心血管病电子杂志, 2018, 6(34):71. doi: 10.16282/j.cnki.cn11-9336/r.2018.34.057. doi: 10.16282/j.cnki.cn11-9336/r.2018.34.057
[12]	Schurz H, Daya M, Möller M, et al. TLR1, 2, 4, 6 and 9 Variants Associated with Tuberculosis Susceptibility: A Systematic Review and Meta-Analysis. PLoS One, 2015, 10(10):e0139711. doi: 10.1371/journal.pone.0139711. doi: 10.1371/journal.pone.0139711
[13]	Sadki K, Lamsyah H, Rueda B, et al. Analysis of MIF, FCGR2A and FCGR3A gene polymorphisms with susceptibility to pulmonary tuberculosis in Moroccan population. J Genet Genomics, 2010, 37(4):257-264. doi: 10.1016/s1673-8527(09)60044-8. doi: 10.1016/S1673-8527(09)60044-8 pmid: 20439102
[14]	Pieters J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe, 2008, 3(6):399-407. doi: 10.1016/j.chom.2008.05.006. doi: 10.1016/j.chom.2008.05.006 pmid: 18541216
[15]	Boisson-Dupuis S. The monogenic basis of human tuberculosis. Hum Genet, 2020, 139(6/7):1001-1009. doi: 10.1007/s00439-020-02126-6. doi: 10.1007/s00439-020-02126-6 URL
[16]	Ogishi M, Yang R, Aytekin C, et al. Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. Nat Med, 2021, 27(9):1646-1654. doi: 10.1038/s41591-021-01388-5. doi: 10.1038/s41591-021-01388-5 pmid: 34183838
[17]	Pires D, Marques J, Pombo JP, et al. Role of Cathepsins in Mycobacterium tuberculosis Survival in Human Macrophages. Sci Rep, 2016, 6:32247. doi: 10.1038/srep32247. doi: 10.1038/srep32247 URL
[18]	Li F, Feng L, Jin C, et al. LpqT improves mycobacteria survival in macrophages by inhibiting TLR2 mediated inflammatory cytokine expression and cell apoptosis. Tuberculosis (Edinb), 2018, 111:57-66. doi: 10.1016/j.tube.2018.05.007. doi: 10.1016/j.tube.2018.05.007 URL
[19]	Portal-Celhay C, Tufariello JM, Srivastava S, et al. Mycobacterium tuberculosis EsxH inhibits ESCRT-dependent CD4⁺ T-cell activation. Nat Microbiol, 2016, 2:16232. doi: 10.1038/nmicrobiol.2016.232. doi: 10.1038/nmicrobiol.2016.232 pmid: 27918526
[20]	Urazova OI, Novitskii VV, Kolobovnikova YV, et al. Factors of Suppression of Immune Response in Patients with Pulmonary Tuberculosis and Eosinophilia. Bull Exp Biol Med, 2015, 159(3):323-326. doi: 10.1007/s10517-015-2952-3. doi: 10.1007/s10517-015-2952-3 URL
[21]	Wang L, Wu J, Li J, et al. Host-mediated ubiquitination of a mycobacterial protein suppresses immunity. Nature, 2020, 577(7792):682-688. doi: 10.1038/s41586-019-1915-7. doi: 10.1038/s41586-019-1915-7 URL
[22]	中国人民解放军总医院第八医学中心全军结核病研究所/全军结核病防治重点实验室/结核病诊疗新技术北京市重点实验室, 《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础和临床学部. 活动性结核病患者免疫功能状态评估和免疫治疗专家共识(2021年版).中国防痨杂志, 2022, 44(1): 9-27. doi: 10.19982/j.issn.1000-6621.20210680. doi: 10.19982/j.issn.1000-6621.20210680
[23]	Khan TA, Mazhar H, Saleha S, et al. Interferon-Gamma Improves Macrophages Function against M.tuberculosis in Multidrug-Resistant Tuberculosis Patients. Chemother Res Pract, 2016, 2016:7295390. doi: 10.1155/2016/7295390. doi: 10.1155/2016/7295390
[24]	Deretic V, Delgado M, Vergne I, et al. Autophagy in immunity against Mycobacterium tuberculosis: a model system to dissect immunological roles of autophagy. Curr Top Microbiol Immunol, 2009, 335:169-188. doi: 10.1007/978-3-642-00302-8_8. doi: 10.1007/978-3-642-00302-8_8 pmid: 19802565
[25]	吴雪琼, 吴长有. 结核病免疫学. 北京: 人民卫生出版社, 2016.
[26]	刘晓, 吴雪琼. 中药治疗耐多药肺结核的研究进展. 中国防痨杂志, 2016, 38(1): 53-56. doi: 10.3969/j.issn.1000-6621.2016.01.012. doi: 10.3969/j.issn.1000-6621.2016.01.012
[27]	Roy E, Lowrie DB, Jolles SR. Current strategies in TB immunotherapy. Curr Mol Med, 2007, 7(4):373-386. doi: 10.2174/156652407780831557. doi: 10.2174/156652407780831557 pmid: 17584077
[28]	Joshi L, Chelluri LK, Gaddam S. Mesenchymal stromal cell therapy in MDR/XDR tuberculosis: A concise review. Arch Immunol Ther Exp(Warsz), 2015, 63(6): 427-433. doi: 10.1007/s00005-015-0347-9. doi: 10.1007/s00005-015-0347-9
[29]	付亮, 梁娟, 张国良, 等. γδT细胞在结核病免疫治疗的研究及其应用前景. 中国防痨杂志, 2019, 41(6):695-699. doi: 10.3969/j.issn.1000-6621.2019.06.019. doi: 10.3969/j.issn.1000-6621.2019.06.019
[30]	Byeon S, Cho JH, Jung HA, et al. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. Cancer Med, 2020, 9(7):2352-2362. doi: 10.1002/cam4.2868. doi: 10.1002/cam4.2868 URL

结核病免疫辅助治疗现状与挑战

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	邓国防, 王庆文. 重视风湿性疾病合并结核感染的多学科诊治[J]. 中国防痨杂志, 2022, 44(9): 865-868.
[2]	国家感染性疾病临床医学研究中心/深圳市第三人民医院, 北京大学深圳医院, 中国医学科学院北京协和医院, 中国防痨协会, 《中国防痨杂志》编辑委员会, 深圳市炎症与免疫性疾病重点实验室. 风湿性疾病患者合并结核分枝杆菌潜伏感染诊治的专家共识[J]. 中国防痨杂志, 2022, 44(9): 869-879.
[3]	中华医学会结核病学分会超声专业委员会, 中国医师协会介入医师分会超声介入专业委员会单位. 结核性胸膜炎超声诊断、分型及介入治疗专家共识(2022年版)[J]. 中国防痨杂志, 2022, 44(9): 880-897.
[4]	包容, 高建峰, 饶艳. 实验性肺结核病变类型与特点[J]. 中国防痨杂志, 2022, 44(9): 898-905.
[5]	王玉香, 陈秋奇, 余鑫鑫, 詹森林, 张培泽, 邓国防. 3HP方案治疗风湿性疾病合并结核分枝杆菌潜伏感染的前瞻性研究[J]. 中国防痨杂志, 2022, 44(9): 906-910.
[6]	谢静仪, 邹瑞丰, 陈玉兰, 陈永, 刘冬舟, 洪小平. 系统性红斑狼疮合并结核感染临床特征及外周血淋巴细胞亚群分析[J]. 中国防痨杂志, 2022, 44(9): 911-916.
[7]	程晓, 陈哲, 焦雪峰, 杨楠, 刁莎, 倪晓凤, 刘峥, 何思颐, 曾力楠, 万朝敏, 康德英, 吴斌, 应斌武, 张慧, 赵荣生, 张伶俐. 重组结核杆菌融合蛋白(EC)用于诊断结核分枝杆菌感染的有效性和安全性系统评价[J]. 中国防痨杂志, 2022, 44(9): 917-926.
[8]	王倪, 黄飞, 竺丽梅, 曾谊, 张瑞梅, 耿红, 刘学法, 郑建刚, 宗佩兰, 曾忠, 李进岚, 蔡翠, 郭晓红, 钟引, 刘莉, 谢艳, 杜芳芳, 周林, 成诗明. 提高抗结核药品固定剂量复合剂在省市级结核病定点医院推广使用的实施性研究[J]. 中国防痨杂志, 2022, 44(9): 927-933.
[9]	魏赣辉, 张加成, 邱小伟. 容积CT值量化判断5mm以上肺结核病灶活动性的应用价值[J]. 中国防痨杂志, 2022, 44(9): 934-939.
[10]	王潮虹, 孙晴, 廖鑫磊, 晏君, 王晨倩, 姜广路, 王芬, 薛毅, 黄海荣, 王桂荣. 231例脊柱结核患者耐药情况分析[J]. 中国防痨杂志, 2022, 44(9): 940-946.
[11]	聂廷月, 陈伟, 张洁莹, 曹红, 钱冰, 顾颖强, 刘旭祥. 2009—2020年合肥市肺结核空间特征分析[J]. 中国防痨杂志, 2022, 44(9): 947-953.
[12]	吴文琪, 钟剑球, 何娟, 邓国防, 王庆文. 风湿性疾病患者结核分枝杆菌潜伏感染激活机制的研究进展[J]. 中国防痨杂志, 2022, 44(9): 954-959.
[13]	陈秋奇, 韩婷婷, 王庆文, 邓国防. 风湿性疾病合并结核分枝杆菌潜伏感染的诊治进展[J]. 中国防痨杂志, 2022, 44(9): 960-965.
[14]	韩旭, 关尚琪, 石银朋, 梅轶芳. 非肿瘤坏死因子靶向药物治疗类风湿关节炎的结核感染风险研究进展[J]. 中国防痨杂志, 2022, 44(9): 966-972.
[15]	姚蓉, 陆宇. 抗结核药物贝达喹啉的耐药情况及其耐药机制研究进展[J]. 中国防痨杂志, 2022, 44(9): 973-977.